Latest news with #ADEM
Yahoo
10 hours ago
- Health
- Yahoo
Demyelinating Diseases Therapeutics Market to Reach USD 45 Billion by 2034, Growing at 6.3% CAGR
Demyelinating Diseases Therapeutics Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- The global market for demyelinating diseases therapeutics is witnessing notable growth and transformation, fueled by the increasing prevalence of neurological disorders and the introduction of innovative treatment solutions. Valued at approximately USD 25 billion in 2024, the market is projected to reach an estimated USD 45 billion by 2034, progressing at a steady Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period from 2025 to 2034. Download PDF Brochure: A major contributor to this expansion is the rising incidence of multiple sclerosis (MS), along with other related disorders such as neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and chronic inflammatory demyelinating polyneuropathy (CIDP). The market is undergoing significant advancements through personalized medicine, biologics, and digital health integrations, shaping the way therapies are developed and delivered. Market Segmentation: A Detailed Breakdown The demyelinating diseases therapeutics market is categorized across several parameters including product type, therapeutic application, disease type, route of administration, distribution channels, therapeutic class, and patient demographics. Among product types, monoclonal antibodies, corticosteroids, and immunomodulators dominate due to their high efficacy and role in managing autoimmune responses central to these diseases. Multiple Sclerosis (MS) remains the largest disease segment due to its global prevalence, impacting nearly 2.8 million individuals worldwide. This segment benefits from a strong drug pipeline and sustained investment in research and development. In contrast, diseases like NMO and CIDP, though less prevalent, are becoming more prominent due to improved diagnostic capabilities and novel drug approvals. When it comes to therapeutic applications, Disease-Modifying Therapies (DMTs) are pivotal. These therapies reduce relapse rates and slow disease progression, particularly in MS, capturing the lion's share of the market. Symptomatic treatments, though secondary in market size, are essential for improving patients' quality of life and remain indispensable in overall disease management strategies. Route of Administration and Distribution Channels The preferred routes of administration in this market include injectable, oral, and infusion-based methods. Injectables lead due to their rapid efficacy and widespread use in administering monoclonal antibodies. However, oral therapies are quickly gaining popularity for their convenience and higher patient adherence, which could shift the administration landscape in coming years. From a distribution perspective, hospital pharmacies remain the dominant channel, especially for therapies requiring medical supervision or administration. Meanwhile, online pharmacies are emerging as strong contenders due to their convenience and role in chronic disease management. This growth is driven by increased internet penetration, telehealth services, and changing consumer behavior. Therapeutic Class and Demographic Insights In terms of therapeutic classification, biologics are leading the charge. These include monoclonal antibodies and recombinant proteins that target specific immune pathways. Biologics offer superior efficacy and fewer side effects, making them the preferred option in many treatment regimens. However, small molecules continue to hold value due to their affordability, oral availability, and ease of production, especially in cost-sensitive markets. Demographically, adult patients comprise the majority due to the typical onset age of MS and related disorders. However, pediatric treatments are on the rise as early diagnosis improves. The geriatric population is another growing segment, supported by the aging global population and increasing incidence of neurological conditions in older adults. These patients often require specialized care due to comorbidities and age-related drug interactions. Browse full Report - Market SegmentationType of Demyelinating Disease - Multiple Sclerosis (MS) - Neuromyelitis Optica (NMO) - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Acute Disseminated Encephalomyelitis (ADEM) Therapeutic Application - Disease-Modifying Therapies (DMTs) - Symptomatic Treatments - Corticosteroids - Monoclonal Antibodies - Other Immunotherapies & Supportive Care Route of Administration - Oral - Injectable (Subcutaneous, Intravenous) - Infusion Distribution Channel - Hospital Pharmacy - Retail Pharmacy - Online Pharmacy Therapeutic Class - Biologics - Small Molecules - Non-Biologics Patient Demographics - Adults - Pediatric - Geriatric Regional Insights and Global Landscape North America currently commands the largest market share, accounting for around 45% of global revenue in 2024. This dominance is underpinned by advanced healthcare systems, widespread access to therapies, and high levels of R&D investment. The U.S., in particular, plays a significant role with supportive regulatory policies and well-established pharmaceutical players. Europe follows closely, contributing approximately 30% to the market. Growth in this region is propelled by increasing awareness, government-supported healthcare systems, and a favorable environment for clinical research. Countries like Germany, France, and the UK are key hubs for drug development and patient care. The Asia-Pacific region is the fastest-growing market with a projected CAGR of 8% through 2034. Factors such as economic development, expanding healthcare infrastructure, and rising disease prevalence contribute to this rapid growth. Nations like China, India, and Japan are investing heavily in healthcare, which supports both access and innovation in therapeutic offerings. Latin America and the Middle East & Africa are also emerging as regions with untapped market potential. While they currently hold smaller shares, their projected CAGRs of 7% and 6% respectively reflect strong future growth, particularly in urban centers with improving access to care. Key Market Drivers The momentum in this market is largely attributed to scientific and technological advancements, including the development of next-generation therapies like monoclonal antibodies and targeted biologics. The rise of personalized medicine, where treatments are tailored based on patient-specific genetic and biomarker profiles, is reshaping therapeutic strategies. Regulatory developments are also influential. Accelerated approval pathways, especially for orphan and breakthrough therapies, have reduced time-to-market for promising treatments. In tandem, increased global healthcare spending, particularly in neurological and autoimmune sectors, is bolstering the adoption of advanced therapies. Challenges and Restraints Despite promising growth, the market faces a number of hurdles. One major challenge is the high cost of therapies, especially biologics, which limits access for patients in low- and middle-income regions. Prolonged regulatory approval timelines and complex compliance requirements can also delay product launches and increase costs for manufacturers. Supply chain disruptions, particularly in biopharmaceutical manufacturing, further complicate delivery and availability. The sector is also vulnerable to clinical trial failures, which can derail product pipelines and investor confidence. Additionally, generic and biosimilar competition can undercut revenues once patents expire, necessitating continuous innovation. Buy Now : Opportunities and Emerging Trends The market is rich with opportunities for expansion and innovation. Digital health technologies, such as telemedicine platforms and remote monitoring tools, are increasingly integrated into care pathways, enhancing both outcomes and convenience. These technologies also support real-time data collection and predictive analytics, aiding personalized care. Additionally, emerging markets offer considerable potential for growth. As awareness rises and infrastructure improves, pharmaceutical companies are investing in these regions to tap into large, underserved patient populations. The trend toward strategic partnerships, mergers, and acquisitions is another significant development. Collaborations between pharmaceutical firms and tech companies, particularly in AI-driven drug discovery and patient management, are redefining the way therapies are developed and delivered. Key Competitors Biogen Inc. Novartis International AG Roche Holding AG Sanofi S.A. Celgene Corporation (a Bristol-Myers Squibb Company) Merck KGaA Teva Pharmaceutical Industries Ltd. Genzyme Corporation (a Sanofi Company) EMD Serono, Inc. AbbVie Inc. GSK (GlaxoSmithKline) Vertex Pharmaceuticals Incorporated Pfizer Inc. Janssen Pharmaceuticals (a Johnson & Johnson Company) Horizon Therapeutics plc Recent Strategic Developments Company Name: Biogen Inc. Month & Year: August 2023 Type of Development: Product Launch Detailed Analysis: Biogen launched its latest multiple sclerosis (MS) therapy, an oral medication named Alectinib, in August 2023. This drug represents a significant advancement in the treatment landscape for MS, targeting a previously underserved patient demographic. The launch is crucial as the MS market increasingly shifts toward oral therapies that offer improved safety and convenience over traditional injections. Biogen's investment in clinical studies demonstrates their commitment to addressing unmet clinical needs. The release not only strengthens Biogen's portfolio but also rekindles competitive dynamics in the MS therapeutics market. Other companies may need to accelerate their research and focus on innovative delivery mechanisms to retain market share, indicating a potential uptick in R&D spending across the industry. Company Name: Novartis International AG Month & Year: July 2023 Type of Development: Regulatory Approval Detailed Analysis: In July 2023, Novartis received expedited approval from the FDA for its drug ofatumumab aimed at treating neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, debilitating condition, and this regulatory advancement opens new pathways for patients who have historically faced limited treatment options. This approval underlines a broader trend in the industry towards personalized medicine and targeted therapies. The positive regulatory news also strengthens Novartis's position in the demyelinating diseases market, compelling competitors to prioritize novel therapeutic approaches. As regulatory environments evolve, this approval may set a precedent that encourages pharmaceutical companies to innovate and invest heavily in rare disease therapies. Company Name: AbbVie Inc. Month & Year: September 2023 Type of Development: Merger Detailed Analysis: AbbVie entered a strategic merger with a biotech firm specializing in CNS (central nervous system) diseases in September 2023. This merger is pivotal not only for AbbVie's growth but also signifies a consolidation trend within the CNS therapeutics sector. By integrating innovative technologies and pipeline assets, AbbVie aims to bolster its competitive edge significantly in the demyelinating diseases market. This merger highlights the increasing interconnectedness of the pharmaceutical ecosystem, pivoting around collaboration to enhance therapeutic effectiveness and patient outcomes. Industry observers anticipate that this will prompt increased mergers and acquisitions in the sector as firms seek similar synergies to expedite drug development processes. Company Name: Sanofi S.A. Month & Year: October 2023 Type of Development: Product Launch Detailed Analysis: Sanofi unveiled a new monoclonal antibody therapy for treating relapsing forms of MS in October 2023, expanding its treatment arsenal significantly in this field. The introduction of this therapy reflects a commitment to advancing treatment modalities through innovative science. Furthermore, the development showcases a broader industry trend toward biologics and targeted therapies for demyelinating diseases. Market responses indicate that healthcare professionals and payers are eager for alternatives that provide safety and efficacy. This influx of new treatment options may fuel competitive pressure on existing therapies, leading to potential price adjustments and altering market dynamics. Company Name: Teva Pharmaceutical Industries Ltd. Month & Year: November 2023 Type of Development: Partnership Detailed Analysis: Teva announced a strategic partnership with a technology firm to collaborate on AI-driven approaches to MS treatment and patient management in November 2023. This partnership underscores a growing trend of incorporating technology into healthcare to enhance drug discovery and patient outcomes. By utilizing AI, Teva aims to streamline clinical research and tailor therapies to individual patient needs, thereby enhancing therapeutic efficacy. The collaboration could reshape how the pharmaceutical industry conducts research and develops therapies for demyelinating diseases, prompting competitors to explore similar integrations of advanced technologies, ultimately driving innovation in the market. This report is also available in the following languages : Japanese (脱髄疾患治療薬市場), Korean (탈수초성 질환 치료제 시장), Chinese (脱髓鞘疾病治疗市场), French (Marché des thérapies contre les maladies démyélinisantes), German (Markt für Therapeutika gegen demyelinisierende Erkrankungen), and Italian (Mercato terapeutico delle malattie demielinizzanti), etc. Request Sample Pages: More Research Finding – Human Granulocytic Ehrlichiosis Drug Market The market for drugs targeting Human Granulocytic Ehrlichiosis (HGE) is valued at approximately $320 million. Given the rising incidence of tick-borne diseases and increased awareness among healthcare professionals, the market is projected to grow significantly, reaching an estimated value of $580 million by 2034. This indicates a compound annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Lymphopenia Therapeutics Market The global lymphopenia therapeutics market is valued at approximately $3.2 billion, driven by increasing awareness of immune disorders and advancements in biologics and immunotherapies. The market is projected to grow significantly, reaching an estimated $6.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period of 2025 to 2034. Cytochrome C Antibody Market The global Cytochrome C Antibody market is valued at approximately $210 million in 2024, driven by increasing research activities in cell apoptosis and related diseases. The market is projected to reach around $350 million by 2034, reflecting a robust growth trajectory fueled by advancements in biotechnology and rising prevalence of cancer and neurodegenerative disorders. AMPK Antibody Market The AMPK antibody market is valued at approximately $1.2 billion, fueled by the growing demand for research products in metabolic diseases and cancer therapy. The market is projected to reach about $2.5 billion by 2034, reflecting accelerating advancements in biotechnology and personalized medicine. Threonine Protein Kinase Chk1 Antibody Insights 2024 The market for Threonine Protein Kinase Chk1 Antibodies is poised for significant growth, with a projected market value of approximately $250 million by 2024. Over the forecast period from 2025 to 2034, the market is expected to expand, reaching an estimated value of $500 million. This growth represents a compound annual growth rate (CAGR) of around 8.5%. TrkC Antibody Market The TrkC antibody market was valued at approximately $1.5 billion in 2024, driven by increasing research funding and rising demand for targeted cancer therapies. This niche market is expected to reach around $3.2 billion by 2034, reflecting a robust growth trajectory. The projected Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 8.2%. Androgen Antibody Market The androgen antibody market is poised for significant growth, with an estimated market value of approximately $1.2 billion in 2024. Projections indicate that this market could expand to around $2.8 billion by 2034, reflecting increasing demand for advanced diagnostic and therapeutic options in conditions related to androgen imbalance. This growth represents a Compound Annual Growth Rate (CAGR) of about 9.0% during the forecast period from 2025 to 2034. Herpesvirus Entry Mediator HVEM Protein Market The global market for the Herpesvirus Entry Mediator (HVEM) protein is valued at approximately $150 million, primarily driven by its applications in immunotherapy and viral research. The market is poised for significant growth, with a projected value of $300 million by 2034, representing a robust Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period from 2025 to 2034. Histone Deacetylase 1 HDAC1 Antibody Market The market for Histone Deacetylase 1 (HDAC1) antibodies is poised for significant growth, valued at approximately $250 million in 2024. This sector is expected to reach an estimated $750 million by 2034, driven by the rising prevalence of cancer and neurodegenerative diseases, which HDAC1 inhibitors target. The compound annual growth rate (CAGR) is projected at approximately 12% during the forecast period from 2025 to 2034. Prostaglandin-endoperoxide Synthase 2 COX-2 Antibody Market The global market for Prostaglandin-endoperoxide Synthase 2 (COX-2) antibodies is valued at approximately $1.6 billion in 2024, with a projected market value of around $3.2 billion by 2034. This growth corresponds to a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. Fecal Incontinence Therapeutics Market The fecal incontinence therapeutics market is poised for significant growth, valued at approximately $1.2 billion in 2024. By 2034, this market is projected to reach around $3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period of 2025–2034. POEMS Syndrome Treatment Market The global market for POEMS Syndrome diagnostic and therapeutic solutions is valued at approximately $700 million. The market is poised for significant growth, with projections estimating a market value of around $1.3 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.5% during the forecast period from 2025 to 2034. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market The Non-Alcoholic Steatohepatitis (NASH) therapeutics and diagnostics market was valued at approximately $4.2 billion in 2024 and is projected to reach $12 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of around 12% during the forecast period of 2025-2034. mRNA Vaccine and Therapeutics Raw Material Market The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034. Gene Editing Kit Market The gene editing kit market is projected to reach a value of approximately $5.4 billion in 2024, driven by advancements in CRISPR technology and increased applications in synthetic biology and personalized medicine. The market is expected to grow significantly, with a forecasted value of $13.2 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period from 2025 to 2034. Nanoparticles Market The global nanoparticles market is projected to reach a value of approximately $60 billion in 2024, driven by advancements in nanotechnology across various sectors, including healthcare, electronics, and energy. The market is expected to grow significantly, achieving a projected value of $120 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Bispecific T Cell Engager Therapeutics Future Trends The bispecific T cell engager (BiTE) therapeutics market is valued at approximately $7.5 billion, driven by rising incidences of hematologic malignancies and solid tumors. The market is projected to grow significantly, with an estimated value of around $20 billion by 2034. This represents a compound annual growth rate (CAGR) of about 12.3% over the forecast period from 2025 to 2034. Molecular Cancer Therapeutics Market The global molecular cancer therapeutics market is projected to reach approximately $120 billion in 2024, driven by advancements in personalized medicine and an increasing number of targeted therapies. The market is expected to grow at a robust CAGR of 8.5% from 2025 to 2034, indicating a significant demand for innovative treatments that address specific genetic and molecular profiles of tumors. Single-Cell Dispenser Market The global single-cell dispenser market is valued at approximately $580 million in 2024 and is projected to reach around $1.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
Yahoo
7 days ago
- General
- Yahoo
State grants approved to begin Strain Road drainage repair
ATHENS, Ala. (WHNT) – Relief may be on the way for homeowners after complaining for years that infrastructure issues have been ignored by city officials. People who live in the historically black neighborhood on Strain Road have been asking Athens officials to do something about the flooding and sewage that have ruined their homes. 1 dead, 1 in custody after early morning shooting on Binford Drive in Huntsville Marks informed the homeowners that, due to age and neglect, an upgrade will cost the city millions, but now that money is finally on the way. In December 2024, the city of Athens partnered with Communities Unlimited to submit a pre-application to the Alabama Department of Environmental Management (ADEM) for grants totaling an estimated $16 million for the project. On Thursday, ADEM agreed to the grants for the preliminary design work totaling $4,517,617.62 so that the repairs can finally begin. In a statement to News 19, Marks said about the funding approval. Body found on Whitesburg Bridge, death ruled as homicide 'At its May 19 meeting, the Athens City Council authorized me to sign the ADEM agreements for the funding,' he said. 'We are eager to get this done and excited to finally have the funds available from ADEM.' For homeowner Kirk Parker, the news regarding the grant approval may take time to sink in. The flooding caused permanent damage to his home of 60 years as he watched the city build several new housing developments just blocks from Strain Road. 'Whatever the next step is going to be, we're going to have to take it, whatever it is, but we need something done about this situation,' said Parker. The Limestone County NAACP backed the homeowners when they faced city council leaders on multiple occasions. 'We're feeling very certain that the new construction they're making it where the flooding and the storm waters are coming their way in full force and it's so unfortunate,' Steele said. You can find more about the Strain Road Project on the City of Athens' website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
21-05-2025
- Health
- Yahoo
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
LOS ANGELES, May 21, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation ('Trethera'), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will assist in evaluating the clinical development of Trethera's lead asset, TRE-515, in demyelinating autoimmune diseases. A demyelinating disease is any condition that causes damage to the protective covering (myelin sheath) that surrounds nerve fibers. When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems. Dr. Greenberg is an internationally recognized neurologist specializing in rare autoimmune disorders of the central nervous system. He currently serves as Vice Chair of Clinical and Translational Research and Professor of Neurology and Pediatrics at UT Southwestern Medical Center. Dr. Greenberg completed his medical degree at Baylor College of Medicine, followed by an internal medicine internship at Rush–St. Luke's Presbyterian Hospital and a neurology residency at Johns Hopkins Hospital, where he later served as co-director of the Transverse Myelitis Center. Since joining UT Southwestern in 2009, he has founded multiple pioneering programs, including the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program. 'It's fantastic to have Dr. Greenberg join our team,' said Immunology Advisory Board Chairman Dr. Peter M. Clark of UCLA. 'With his addition, we now have an exceptional and purpose-driven team at Trethera with the world's foremost experts from Harvard, Stanford, and UT Southwestern to provide scientific answers as well as enroll patients in our forthcoming neuroimmunology Phase 1 clinical trials to transform patient care.' 'I'm honored to have Dr. Greenberg join the Scientific Advisory Board and support the advancement of TRE-515 as a potential treatment for patients with rare demyelinating diseases,' said Dr. Ken Schultz, Chairman and CEO of Trethera. 'Safe and effective treatments for these neurologic conditions represent a significant unmet need, particularly in pediatric populations, where existing therapies often carry substantial side effects and deliver inconsistent results.' Dr. Greenberg's research and clinical expertise focus on demyelinating and inflammatory disorders such as acute disseminated encephalomyelitis (ADEM), optic neuritis, neuromyelitis optica spectrum disorder (NMOSD), and transverse myelitis. As the principal investigator of major national collaborative studies, he has contributed extensively to the discovery of novel biomarkers and the development of biorepository protocols that support precision diagnostics and treatment strategies. Dr. Greenberg's appointment to the Scientific Advisory Board further strengthens Trethera's commitment to advancing innovative therapies for autoimmune neurologic diseases. Trethera's clinical stage and first-in-class drug, TRE-515, holds FDA Orphan Drug status for both optic neuritis and ADEM. FDA Orphan Drug designation confers substantial advantages, including a faster path to market approval, FDA assistance in designing clinical trials, exemption from the $4M drug approval application fee, and eligibility for seven years of marketing exclusivity. Should the FDA approve TRE-515 for commercial use in ADEM, Trethera would be eligible for a pediatric priority review voucher. TRE-515 is currently being evaluated in a Phase 1 dose escalation solid tumors clinical trial. ADEM is an autoimmune disease, affecting 15,000 patients a year in the United States, with most cases occurring in six to eight year-old children. ADEM can present with fever and difficulty walking that progresses to loss of consciousness, coma, and even death. Optic neuritis typically occurs in adult patients, manifesting with rapid vision loss in one or both eyes, with up to one in four patients never fully recovering their eyesight. Over 100,000 cases of optic neuritis occur annually in the US and have a close association with multiple sclerosis (MS). Figure 1: Representative stained sections of the optic nerve from mice experiencing optic neuritis. Arrows point to regions of leukocyte infiltration. Sources: Cleveland Clinic 2021; Bennett 2019; Yang 2017; Wilhelm 2015 About Trethera Trethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients. For more information, please visit us at or e-mail Investor Relations at ir@ You can also follow Trethera on Facebook and LinkedIn. Note on Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are 'forward-looking statements,' which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera's control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. A photo accompanying this announcement is available at in to access your portfolio
Yahoo
18-05-2025
- Health
- Yahoo
ADPH releases 2025 fish consumption advisories
HUNTSVILLE, Ala. (WHNT) — People looking to eat the fish they catch may benefit from reading the 2025 fish consumption advisories. ADPH annually updates the fish consumption advisories based on data gathered by the Alabama Department of Environmental Management from the previous fall. 📲 to stay updated on the go. 📧 to have news sent to your inbox. ADEM, the Tennessee Valley Authority and the Alabama Department of Conservation and Natural Resources collected samples of specific fish species to analyze from various bodies of water throughout the state in the fall of 2024. This includes 492 samples from 42 collection stations. ADPH assessed the results to find whether any tested contaminants in the fish could cause potential health effects. The main contaminants in Alabama are: Mercury Polychlorinated biphenyls (PCBs) Perfluoralkyl sulfonate (PFOS) These advisories are issued for specific bodies of water and fish taken from those areas. In reservoirs, advisories apply to waters as far as a boat can be taken upstream to full pool elevations. Recently, ADEM has been putting up signs at many public boat launches with a QR code. The code on the sign can be scanned with a mobile phone and will link to the advisory map. The map can also be found at the ADEM website. Newly issued advisories are the safe amount of fish that can be eaten in a given time, such as meals per week, meals per month or do not eat any. A meal consists of six ounces of cooked fish or eight ounces of raw fish. New and updated consumption advisories released for the 42 bodies of water tested can be found on the ADPH Toxicology website. The advice in the release is offered as a guide for people who want to eat fish they catch from the various bodies of water throughout Alabama. However, no regulations ban the consumption of any of the fish caught within the state, nor is there a risk of an acute toxic episode that could happen from eating any of the fish containing the contaminants, which the State has done tests on. A general rule of thumb is that older, larger fish have eaten more and have been in the water longer, so there is a higher chance for contaminants being in their bodies. A fish consumption advisory can be issued for one or more specific species of fish within a body of water, or an advisory can be extended to include all fish species there. When excess levels of a contaminant are found in a specific species of fish, an advisory is issued for that specific species. When excess levels of a contaminant are found in multiple fish species sampled from a specific body of water, a Do Not Eat Any advisory would be issued. Eating a fish from an area under a Do Not Eat Any advisory may put the consumer at risk for harm. If a species is listed in the advisory, it is safe to assume that a similar species with similar feeding habits should be eaten with caution. For example, if black crappie is listed and white crappie is not, because they are in the same family, all crappie would fall under the listed advisory. To see the full list of contaminated fish in Alabama, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
USA Today
01-05-2025
- Health
- USA Today
Boston Marathon runner makes miraculous journey from paralyzation to finishing the race
Boston Marathon runner makes miraculous journey from paralyzation to finishing the race Show Caption Hide Caption Runner makes miraculous recovery from hospital bed to Boston Marathon After battling a rare autoimmune disease that left her paralyzed, Alex Mayer defied the odds by running and finishing the 2025 Boston Marathon. For runner Alex Mayer, competing in the Boston Marathon was about more than just reaching the finish line. In January 2023, Alex woke up in a hospital bed with no idea how she got there. Confused and unable to move, with no short-term memory and cognitively impaired, Alex was soon diagnosed with acute disseminated encephalomyelitis (ADEM). This rare autoimmune disease can attack the nervous system, making the victim unable to process information or perform basic tasks without support. "It was difficult to come to terms with the fact that not only could I not walk or move, but also my identity had been altered," Alex recalled. The recovery process was slow. Alex had to relearn basic skills. She also had to accept a new reality and face fresh challenges, including physical therapy, isolation, and a drastically altered college experience. "The hardest part of my recovery was trying to accept that this had happened," said Alex. "I was forever changed, and not everyone around me would be able to understand what that was like." Once she started physical therapy, she began setting new goals, like standing on one foot, closing her eyes without falling over, walking without a cane, and eventually running. Inspired by watching the Boston Marathon in 2024, she targeted running the marathon herself as her ultimate goal. Watch this runner's journey from being unable to walk to finishing The Boston Marathon below. Alex trained hard! "Every time I didn't want to run, I reminded myself that I am so lucky to be here and I remembered the girl in the hospital bed begging to be let out," she said. Her training paid off! With friends and family supporting her every step of the way, she achieved her goal of running the marathon and proudly crossed the finish line with an overwhelming sense of gratitude. "Yes, she ran a marathon," said Claire Rose, one of Alex's best friends. "But more importantly, the whole weekend felt like a celebration of how far she had come, both physically and mentally." Humankind is your go-to spot for good news! Click here to submit your uplifting, cute, or inspiring video moments for us to feature. Also, click here to subscribe to our newsletter, bringing our top stories of the week straight to your inbox.
